Lipid disorders and their relevance to outcomes in chronic kidney disease.
about
Modified Lipids and Lipoproteins in Chronic Kidney Disease: A New Class of Uremic ToxinsDyslipidemia, kidney disease, and cardiovascular disease in diabetic patients.Relation of serum lipids and lipoproteins with progression of CKD: The CRIC study.Macrophage-derived apoESendai suppresses atherosclerosis while causing lipoprotein glomerulopathy in hyperlipidemic mice.Triglyceride levels are closely associated with mild declines in estimated glomerular filtration rates in middle-aged and elderly Chinese with normal serum lipid levels.Metabolism, energetics, and lipid biology in the podocyte - cellular cholesterol-mediated glomerular injury.Mid-adulthood risk factor profiles for CKDAssociation of dyslipidemia with renal outcomes in chronic kidney disease.Effect of uremia on structure and function of immune system.Markers of increased atherosclerotic risk in patients with chronic kidney disease: a preliminary study.Post-transcriptional nature of uremia-induced downregulation of hepatic apolipoprotein A-I production.Targeting the transcription factor Nrf2 to ameliorate oxidative stress and inflammation in chronic kidney diseaseThe effect of adropin on lipid and glucose metabolism in rats with hyperlipidemia.Serum lipoprotein changes in dogs with renal disease.Randomized, controlled trial of glucose-sparing peritoneal dialysis in diabetic patients.Effect of methoxy polyethylene glycol-epoetin beta on oxidative stress in predialysis patients with chronic kidney disease.Lipotoxicity and cardiac dysfunction in mammals and Drosophila.Statins in the management of dyslipidemia associated with chronic kidney disease.Reasons for the lack of salutary effects of cholesterol-lowering interventions in end-stage renal disease populations.Role of dyslipidemia in impairment of energy metabolism, oxidative stress, inflammation and cardiovascular disease in chronic kidney disease.Influenza vaccination in patients with end-stage renal disease.Evaluation of Nutritional Biochemical Parameters in Haemodialysis Patients over a Ten-year PeriodTriglyceride Treatment in the Age of Cholesterol Reduction.Dyslipidemia in patients with chronic kidney disease.Lipid (per) oxidation in mitochondria: an emerging target in the ageing process?Lipoprotein lipase deficiency in chronic kidney disease is accompanied by down-regulation of endothelial GPIHBP1 expression.Top-down lipidomics of low density lipoprotein reveal altered lipid profiles in advanced chronic kidney diseaseRed yeast rice repairs kidney damage and reduces inflammatory transcription factors in rat models of hyperlipidemia.Dysregulation of hepatic fatty acid metabolism in chronic kidney disease.Novel inflammatory marker in dialysis patients: YKL-40.Effect of hepatic and renal impairment on the pharmacokinetics of dalcetrapib: altered distribution of the active thiol?The link between phenotype and fatty acid metabolism in advanced chronic kidney disease.Beneficial effect of genistein on lowering blood pressure and kidney toxicity in fructose-fed hypertensive rats.Greater low-density lipoprotein cholesterol variability is associated with increased progression to dialysis in patients with chronic kidney disease stage 3.Longitudinal Trend in Lipid Profile of Incident Peritoneal Dialysis Patients is Not Influenced by the Use of Biocompatible Solutions.Tinzaparin provides lower lipid profiles in maintenance hemodialysis patients: a cross-sectional observational study
P2860
Q28074264-1BED8C3A-BC1B-4580-B58F-77878140F577Q33776181-FE2CFF06-A087-4457-97D0-9A6E3EF7B754Q33835707-93597859-74A6-4902-B7D6-45B3CC1014ACQ34238672-D2826901-BBB3-4F35-AE60-8E3BF1CD1FE8Q34281929-C495A348-0FFD-4589-8F40-FD8EA6E188C7Q34336370-077E7F53-6020-47D8-86EC-8D8E1064FFEEQ34427602-CEA2FCCA-A6EF-4171-A0C2-0F75FD797AA5Q34580123-4DB3625A-3517-42B0-8349-12AF3BE01B67Q35635884-D8074D72-80BB-450D-A078-A39E61D251C8Q36538088-66B9A53F-E7C5-486C-8600-3CA7079A22E0Q36721867-6DF61727-662C-424C-A436-3634E2C16795Q36788430-A0D1AAEB-2AA7-4CAD-B226-5706FF28670DQ36805162-7C582304-850A-4750-BE2E-ECF16EBFA0F6Q36975541-6CF438AC-4850-4BD5-935E-2DE08CD0009EQ37260188-DE28D019-D94A-4A20-89F1-CDC2924F6E9FQ37313221-9CB4FF6D-B50D-4318-B706-F1DDAE75677CQ37919531-05610FD8-7F29-4850-8FE0-5B4B554EB62DQ37986355-A8B14898-0D0A-4423-9185-5529946D0458Q38076217-9D410F7C-B22C-4F2A-B0F7-6AFA6C6840BCQ38131300-E4051FEE-9E6A-4313-B049-827F6381BF59Q38516153-48D5C670-1E14-409B-AD23-1ED1D873CEEEQ38598905-12792FCB-F200-4680-915B-2714642A5B4FQ38932760-F2D90F00-1BB0-4EB5-9F36-406BF3FC9DADQ39045120-C6B53CD0-CAAC-4169-BF66-D04F05AEE979Q39328053-13E444B8-BB5B-445B-9404-5CFE7A5B3488Q41980428-22C56713-7D57-4689-97FB-C470FBFE2996Q42786040-9C20A25D-7AA5-4951-82A2-03172D24301FQ42972450-87C61895-300C-46AA-B5F0-7F3264A288BFQ43247391-8311E4D4-F398-46A6-B805-90CDB3879B70Q46103273-F329790B-3C17-4259-857B-D7E2C481D8C9Q46301471-9A7BDDBB-341F-423E-8D6D-576642E2BDCFQ46397367-EE82D0CB-6E33-4EBF-AA5D-66A394E3ABEBQ46539729-313E996D-8E7E-43B7-BA49-828768E1449AQ49588056-8D9D25D9-2584-40C4-A3A5-69B77B4C4410Q53329399-0F56B69E-1BBA-45CE-BD64-20C7DEE3EC3DQ59100353-6106A7AA-EC36-4B9E-9966-DA6AA304DA9C
P2860
Lipid disorders and their relevance to outcomes in chronic kidney disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 10 January 2011
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Lipid disorders and their relevance to outcomes in chronic kidney disease.
@en
Lipid disorders and their relevance to outcomes in chronic kidney disease.
@nl
type
label
Lipid disorders and their relevance to outcomes in chronic kidney disease.
@en
Lipid disorders and their relevance to outcomes in chronic kidney disease.
@nl
prefLabel
Lipid disorders and their relevance to outcomes in chronic kidney disease.
@en
Lipid disorders and their relevance to outcomes in chronic kidney disease.
@nl
P356
P1433
P1476
Lipid disorders and their relevance to outcomes in chronic kidney disease.
@en
P2093
Keith Norris
Nosratola D Vaziri
P304
P356
10.1159/000321845
P577
2011-01-10T00:00:00Z